Table 2.
Immunologic characteristic of recipients with periodontitis
| Variable | Total | Stage I and II | Stage III | Stage IV | p-value |
|---|---|---|---|---|---|
| No. of HLA mismatch | 3.39 ± 1.57 | 3.19 ± 1.61 | 3.61 ± 1.60 | 3.63 ± 1.32 | 0.06 |
| Induction immunosuppressive agent | |||||
| Simulecta | 263 (86.8) | 143 (89.4) | 76 (85.4) | 44 (81.5) | 0.12 |
| Maintenance immunosuppressive agent (initial) | |||||
| Tacrolimus-based regimenb | 285 (94.1) | 150 (93.8) | 82 (92.1) | 53 (98.1) | 0.26 |
| Maintenance immunosuppressive agent (at 1 yr) | |||||
| Tacrolimus-based regimen | 249 (91.5) | 131 (92.3) | 71 (88.7) | 47 (94.0) | 0.95 |
| Tacrolimus + mycophenolate | 207 (76.1) | 105 (73.9) | 60 (75.0) | 42 (84.0) | 0.20 |
| Tacrolimus + sirolimus | 27 (9.9) | 16 (11.3) | 9 (11.3) | 2 (4.0) | 0.20 |
| Tacrolimus + bredinin | 15 (5.5) | 10 (7.0) | 2 (2.5) | 3 (6.0) | 0.51 |
| Cyclosporine + mycophenolate | 23 (8.5) | 11 (7.7) | 9 (11.3) | 3 (6.0) | 0.95 |
Data are expressed as mean ± standard deviation or number (%).
HLA, human leukocyte antigen.
a
Simulect or anti-thymocyte globulin were used as induction immunosuppressive agent.
b
Initial maintenance immunosuppressive agent was tacrolimus- or cyclosporine-based regimen.